
ACOG Stock Forecast & Price Target
ACOG Analyst Ratings
Bulls say
Alpha Cognition is currently undervalued with a total enterprise value of $520M, assuming peak annual sales of $540M for ZUNVEYL in the US and employing a 12% discount rate and a 3% terminal rate of decline. There is potential for growth as the company focuses on increasing sales through differentiation, addressing key issues with current treatments, and seeking partnerships for additional indications and formulations. Risks include potential setbacks in clinical testing and slower market uptake of ZUNVEYL due to pricing pressures and competition, which could lead to medium to long-term dilution risk.
Bears say
Alpha Cognition is facing a negative outlook due to its limited commercial success with ZUNVEYL and ongoing clinical trials. Despite beating top and bottom-line expectations, the company's financials remain weak and it is projected to not reach profitability until 2027. The recent early settlement agreement to erase future royalty and milestone payments indicates potential financial struggles and the stock may continue to underperform.
This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.
ACOG Analyst Forecast & Price Prediction
Start investing in ACOG
Order type
Buy in
Order amount
Est. shares
0 shares